Analyst Brandon Folkes of H.C. Wainwright reiterated a Buy rating on Omeros, retaining the price target of $9.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Brandon Folkes has given his Buy rating due to a combination of factors including the promising clinical data for narsoplimab, which is highlighted in a recent publication in the American Journal of Hematology. The data underscores narsoplimab’s potential as a first-in-class therapy for transplant-associated thrombotic microangiopathy (TA-TMA), showing significant survival benefits in both adult and pediatric patients, even those with severe disease who are refractory to existing treatments.
The Expanded Access Program results, which involved 136 patients across 28 global centers, demonstrated improved one-year overall survival rates compared to historical benchmarks, particularly in high-risk groups. Narsoplimab’s unique mechanism of action, targeting the lectin pathway of complement activation, offers a differentiated approach that may enhance safety by preserving immune function. These clinical outcomes and the absence of new safety concerns position narsoplimab as a valuable asset for Omeros, justifying the Buy rating.
Folkes covers the Healthcare sector, focusing on stocks such as Omeros, Eupraxia Pharmaceuticals, and MannKind. According to TipRanks, Folkes has an average return of -4.1% and a 37.37% success rate on recommended stocks.